{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:14:21Z","timestamp":1789013661267,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00277-022-04955-z","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T09:04:50Z","timestamp":1661850290000},"page":"2241-2255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory"],"prefix":"10.1007","volume":"101","author":[{"given":"Sandrine","family":"Saugues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Daguenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyacinthe Johnson","family":"Ansah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Turhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Guerci-Bresler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre\u00ef","family":"Tchirkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalil","family":"Hamroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hermet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1858-0587","authenticated-orcid":false,"given":"Marc G.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"4955_CR1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031\u20131037. https:\/\/doi.org\/10.1056\/NEJM200104053441401","journal-title":"N Engl J Med"},{"key":"4955_CR2","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa022457","journal-title":"N Engl J Med"},{"key":"4955_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","volume":"14","author":"G Rosti","year":"2017","unstructured":"Rosti G, Castagnetti F, Gugliotta G, Baccarani M (2017) Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol 14:141\u2013154. https:\/\/doi.org\/10.1038\/nrclinonc.2016.139","journal-title":"Nat Rev Clin Oncol"},{"key":"4955_CR4","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","volume":"2","author":"K Sasaki","year":"2015","unstructured":"Sasaki K, Strom SS, O\u2019Brien S et al (2015) Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2:e186-193. https:\/\/doi.org\/10.1016\/S2352-3026(15)00048-4","journal-title":"Lancet Haematol"},{"key":"4955_CR5","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW et al (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol Off J Am Soc Clin Oncol 34:2851\u20132857. https:\/\/doi.org\/10.1200\/JCO.2015.66.2866","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4955_CR6","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.3324\/haematol.2019.240739","volume":"105","author":"S Branford","year":"2020","unstructured":"Branford S (2020) Why is it critical to achieve a deep molecular response in chronic myeloid leukemia? Haematologica 105:2730\u20132737. https:\/\/doi.org\/10.3324\/haematol.2019.240739","journal-title":"Haematologica"},{"key":"4955_CR7","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809\u20131820. https:\/\/doi.org\/10.1182\/blood-2006-02-005686","journal-title":"Blood"},{"key":"4955_CR8","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol Off J Am Soc Clin Oncol 27:6041\u20136051. https:\/\/doi.org\/10.1200\/JCO.2009.25.0779","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4955_CR9","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884. https:\/\/doi.org\/10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"key":"4955_CR10","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"4955_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","volume":"128","author":"TP Hughes","year":"2016","unstructured":"Hughes TP, Ross DM (2016) Moving treatment-free remission into mainstream clinical practice in CML. Blood 128:17\u201323. https:\/\/doi.org\/10.1182\/blood-2016-01-694265","journal-title":"Blood"},{"key":"4955_CR12","doi-asserted-by":"publisher","unstructured":"Hochhaus A, Saussele S, Rosti G, et al (2017) Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 28:iv41\u2013iv51. https:\/\/doi.org\/10.1093\/annonc\/mdx219","DOI":"10.1093\/annonc\/mdx219"},{"key":"4955_CR13","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","volume":"16","author":"JP Radich","year":"2018","unstructured":"Radich JP, Deininger M, Abboud CN et al (2018) Chronic myeloid leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16:1108\u20131135. https:\/\/doi.org\/10.6004\/jnccn.2018.0071","journal-title":"J Natl Compr Canc Netw"},{"key":"4955_CR14","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3389\/fonc.2020.00883","volume":"10","author":"M Annunziata","year":"2020","unstructured":"Annunziata M, Bonifacio M, Breccia M et al (2020) Current strategies and future directions to achieve deep molecular response and treatment-free remission in chronic myeloid leukemia. Front Oncol 10:883. https:\/\/doi.org\/10.3389\/fonc.2020.00883","journal-title":"Front Oncol"},{"key":"4955_CR15","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1097\/HS9.0000000000000468","volume":"4","author":"R Hehlmann","year":"2020","unstructured":"Hehlmann R (2020) Chronic Myeloid Leukemia in 2020. HemaSphere 4:e468. https:\/\/doi.org\/10.1097\/HS9.0000000000000468","journal-title":"HemaSphere"},{"key":"4955_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajh.22037","volume":"86","author":"KJ Aichberger","year":"2011","unstructured":"Aichberger KJ, Herndlhofer S, Schernthaner G-H et al (2011) Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 86:533\u2013539. https:\/\/doi.org\/10.1002\/ajh.22037","journal-title":"Am J Hematol"},{"key":"4955_CR17","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jnci\/djr292","volume":"103","author":"P Le Coutre","year":"2011","unstructured":"Le Coutre P, Rea D, Abruzzese E et al (2011) Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 103:1347\u20131348. https:\/\/doi.org\/10.1093\/jnci\/djr292","journal-title":"J Natl Cancer Inst"},{"key":"4955_CR18","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy: Increasing CML Prevalence. Cancer 118:3123\u20133127. https:\/\/doi.org\/10.1002\/cncr.26679","journal-title":"Cancer"},{"key":"4955_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H (2020) Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol 95:691\u2013709. https:\/\/doi.org\/10.1002\/ajh.25792","journal-title":"Am J Hematol"},{"key":"4955_CR20","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1002\/cncr.31411","volume":"124","author":"D Rea","year":"2018","unstructured":"Rea D, Ame S, Berger M et al (2018) Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group: TKI Discontinuation in Clinical Practice. Cancer 124:2956\u20132963. https:\/\/doi.org\/10.1002\/cncr.31411","journal-title":"Cancer"},{"key":"4955_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S et al (2016) Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 30:48\u201356. https:\/\/doi.org\/10.1038\/leu.2015.261","journal-title":"Leukemia"},{"key":"4955_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.bulcan.2019.05.011","volume":"107","author":"J-M Cayuela","year":"2020","unstructured":"Cayuela J-M, Chomel J-C, Coiteux V et al (2020) Recommandations du France Intergroupe des leuc\u00e9mies my\u00e9lo\u00efdes chroniques (Fi-LMC) pour l\u2019examen des mutations du domaine kinase de BCR-ABL1 dans la leuc\u00e9mie my\u00e9lo\u00efde chronique. Bull Cancer (Paris) 107:113\u2013128. https:\/\/doi.org\/10.1016\/j.bulcan.2019.05.011","journal-title":"Bull Cancer (Paris)"},{"key":"4955_CR23","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260\u20132270. https:\/\/doi.org\/10.1056\/NEJMoa1002315","journal-title":"N Engl J Med"},{"key":"4955_CR24","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259. https:\/\/doi.org\/10.1056\/NEJMoa0912614","journal-title":"N Engl J Med"},{"key":"4955_CR25","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim D-W, Kantarjian HM et al (2012) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 30:3486\u20133492. https:\/\/doi.org\/10.1200\/JCO.2011.38.7522","journal-title":"J Clin Oncol"},{"key":"4955_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.13108","volume":"168","author":"TH Br\u00fcmmendorf","year":"2015","unstructured":"Br\u00fcmmendorf TH, Cortes JE, Souza CA et al (2015) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol 168:69\u201381. https:\/\/doi.org\/10.1111\/bjh.13108","journal-title":"Br J Haematol"},{"key":"4955_CR27","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM et al (2016) Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol 34:2333\u20132340. https:\/\/doi.org\/10.1200\/JCO.2015.64.8899","journal-title":"J Clin Oncol"},{"key":"4955_CR28","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"JH Lipton","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A et al (2016) Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol 17:612\u2013621. https:\/\/doi.org\/10.1016\/S1470-2045(16)00080-2","journal-title":"Lancet Oncol"},{"key":"4955_CR29","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP et al (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30:1044\u20131054. https:\/\/doi.org\/10.1038\/leu.2016.5","journal-title":"Leukemia"},{"key":"4955_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW et al (2018) Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol 36:231\u2013237. https:\/\/doi.org\/10.1200\/JCO.2017.74.7162","journal-title":"J Clin Oncol"},{"key":"4955_CR31","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/bjh.13983","volume":"176","author":"D Ferrero","year":"2017","unstructured":"Ferrero D, Cerrano M, Cris\u00e0 E et al (2017) How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience. Br J Haematol 176:669\u2013671. https:\/\/doi.org\/10.1111\/bjh.13983","journal-title":"Br J Haematol"},{"key":"4955_CR32","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3324\/haematol.2017.174953","volume":"102","author":"IGP Geelen","year":"2017","unstructured":"Geelen IGP, Thielen N, Janssen JJWM et al (2017) Treatment outcome in a population-based, \u201creal-world\u201d cohort of patients with chronic myeloid leukemia. Haematologica 102:1842\u20131849. https:\/\/doi.org\/10.3324\/haematol.2017.174953","journal-title":"Haematologica"},{"key":"4955_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.exphem.2018.05.003","volume":"64","author":"FE Nicolini","year":"2018","unstructured":"Nicolini FE, Alcazer V, Cony-Makhoul P et al (2018) Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib. Exp Hematol 64:97-105.e4. https:\/\/doi.org\/10.1016\/j.exphem.2018.05.003","journal-title":"Exp Hematol"},{"key":"4955_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.16733","volume":"192","author":"D Milojkovic","year":"2021","unstructured":"Milojkovic D, Cross NCP, Ali S et al (2021) Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. Br J Haematol 192:62\u201374. https:\/\/doi.org\/10.1111\/bjh.16733","journal-title":"Br J Haematol"},{"key":"4955_CR35","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP et al (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26:2197\u20132203. https:\/\/doi.org\/10.1038\/leu.2012.134","journal-title":"Leukemia"},{"key":"4955_CR36","doi-asserted-by":"crossref","unstructured":"Jabbour E, Kantarjian HM, Saglio G (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood","DOI":"10.1182\/blood-2013-06-511592"},{"key":"4955_CR37","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA et al (2021) Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 35:440\u2013453. https:\/\/doi.org\/10.1038\/s41375-020-01111-2","journal-title":"Leukemia"},{"key":"4955_CR38","doi-asserted-by":"publisher","first-page":"E668","DOI":"10.1002\/ajh.24916","volume":"92","author":"M Breccia","year":"2017","unstructured":"Breccia M, Colafigli G, Molica M et al (2017) Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life. Am J Hematol 92:E668\u2013E670. https:\/\/doi.org\/10.1002\/ajh.24916","journal-title":"Am J Hematol"},{"key":"4955_CR39","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/cncr.32623","volume":"126","author":"L Masarova","year":"2020","unstructured":"Masarova L, Cortes JE, Patel KP et al (2020) Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer 126:1448\u20131459. https:\/\/doi.org\/10.1002\/cncr.32623","journal-title":"Cancer"},{"key":"4955_CR40","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, M\u00fcller MC, Lauseker M et al (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32:415\u2013423. https:\/\/doi.org\/10.1200\/JCO.2013.49.9020","journal-title":"J Clin Oncol"},{"key":"4955_CR41","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L, Saussele S, Lauseker M et al (2015) Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 29:1123\u20131132. https:\/\/doi.org\/10.1038\/leu.2015.36","journal-title":"Leukemia"},{"key":"4955_CR42","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","volume":"121","author":"S Branford","year":"2013","unstructured":"Branford S, Yeung DT, Ross DM et al (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121:3818\u20133824. https:\/\/doi.org\/10.1182\/blood-2012-10-462291","journal-title":"Blood"},{"key":"4955_CR43","doi-asserted-by":"publisher","first-page":"e15222","DOI":"10.1097\/MD.0000000000015222","volume":"98","author":"R Wang","year":"2019","unstructured":"Wang R, Cong Y, Li C et al (2019) Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia. Medicine (Baltimore) 98:e15222. https:\/\/doi.org\/10.1097\/MD.0000000000015222","journal-title":"Medicine (Baltimore)"},{"key":"4955_CR44","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.1016\/S2352-3026(19)30087-0","volume":"6","author":"Y-CT Shih","year":"2019","unstructured":"Shih Y-CT, Cortes JE, Kantarjian HM (2019) Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematol 6:e398\u2013e408. https:\/\/doi.org\/10.1016\/S2352-3026(19)30087-0","journal-title":"Lancet Haematol"},{"key":"4955_CR45","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","volume":"4","author":"C Vener","year":"2020","unstructured":"Vener C, Banzi R, Ambrogi F et al (2020) First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv 4:2723\u20132735. https:\/\/doi.org\/10.1182\/bloodadvances.2019001329","journal-title":"Blood Adv"},{"key":"4955_CR46","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.clml.2015.06.006","volume":"15","author":"NJ Di Bella","year":"2015","unstructured":"Di Bella NJ, Bhowmik D, Bhor M et al (2015) The effectiveness of tyrosine kinase inhibitors and molecular monitoring patterns in newly diagnosed patients with chronic myeloid leukemia in the community setting. Clin Lymphoma Myeloma Leuk 15:599\u2013605. https:\/\/doi.org\/10.1016\/j.clml.2015.06.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4955_CR47","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1185\/03007995.2014.977992","volume":"31","author":"JE Signorovitch","year":"2015","unstructured":"Signorovitch JE, Betts KA, Reichmann WM et al (2015) One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison. Curr Med Res Opin 31:315\u2013322. https:\/\/doi.org\/10.1185\/03007995.2014.977992","journal-title":"Curr Med Res Opin"},{"key":"4955_CR48","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/03007995.2021.1896489","volume":"37","author":"B Muresan","year":"2021","unstructured":"Muresan B, Mamolo C, Cappelleri JC et al (2021) An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia. Curr Med Res Opin 37:801\u2013809. https:\/\/doi.org\/10.1080\/03007995.2021.1896489","journal-title":"Curr Med Res Opin"},{"key":"4955_CR49","doi-asserted-by":"publisher","first-page":"7534","DOI":"10.18632\/oncotarget.23691","volume":"9","author":"M Breccia","year":"2018","unstructured":"Breccia M, Molica M, Colafigli G et al (2018) Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. Oncotarget 9:7534\u20137540. https:\/\/doi.org\/10.18632\/oncotarget.23691","journal-title":"Oncotarget"},{"key":"4955_CR50","doi-asserted-by":"publisher","first-page":"8931","DOI":"10.1002\/cam4.3516","volume":"9","author":"E Sato","year":"2020","unstructured":"Sato E, Iriyama N, Tokuhira M et al (2020) The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort. Cancer Med 9:8931\u20138939. https:\/\/doi.org\/10.1002\/cam4.3516","journal-title":"Cancer Med"},{"key":"4955_CR51","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"F-X Mahon","year":"2010","unstructured":"Mahon F-X, R\u00e9a D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035. https:\/\/doi.org\/10.1016\/S1470-2045(10)70233-3","journal-title":"Lancet Oncol"},{"key":"4955_CR52","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D et al (2017) Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 35:298\u2013305. https:\/\/doi.org\/10.1200\/JCO.2016.68.2914","journal-title":"J Clin Oncol"},{"key":"4955_CR53","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","volume":"25","author":"FE Nicolini","year":"2019","unstructured":"Nicolini FE, Dulucq S, Boureau L et al (2019) Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients. Clin Cancer Res 25:6606\u20136613. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3373","journal-title":"Clin Cancer Res"},{"key":"4955_CR54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2019-124408","volume":"134","author":"D Rea","year":"2019","unstructured":"Rea D, Nicolini FE, Tulliez M et al (2019) Prognostication of molecular relapses after dasatinib or nilotinib discontinuation in chronic myeloid leukemia (CML): a FI-LMC STOP 2G-TKI study update. Blood 134:30\u201330. https:\/\/doi.org\/10.1182\/blood-2019-124408","journal-title":"Blood"},{"key":"4955_CR55","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747\u2013757. https:\/\/doi.org\/10.1016\/S1470-2045(18)30192-X","journal-title":"Lancet Oncol"},{"key":"4955_CR56","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/ajh.24120","volume":"90","author":"S Mori","year":"2015","unstructured":"Mori S, Vagge E, le Coutre P et al (2015) Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study: ISAV study results: age and dPCR predict relapse. Am J Hematol 90:910\u2013914. https:\/\/doi.org\/10.1002\/ajh.24120","journal-title":"Am J Hematol"},{"key":"4955_CR57","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3324\/haematol.2018.205054","volume":"104","author":"C Fava","year":"2019","unstructured":"Fava C, Rege-Cambrin G, Dogliotti I et al (2019) Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica 104:1589\u20131596. https:\/\/doi.org\/10.3324\/haematol.2018.205054","journal-title":"Haematologica"},{"key":"4955_CR58","doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez-Boluda JC, Pereira A, Pastor-Gal\u00e1n I, et al (2018) Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. Blood Cancer J 8:. https:\/\/doi.org\/10.1038\/s41408-018-0125-0","DOI":"10.1038\/s41408-018-0125-0"},{"key":"4955_CR59","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF et al (2019) De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol 6:e375\u2013e383. https:\/\/doi.org\/10.1016\/S2352-3026(19)30094-8","journal-title":"Lancet Haematol"},{"key":"4955_CR60","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bjh.17286","volume":"193","author":"S Claudiani","year":"2021","unstructured":"Claudiani S, Apperley JF, Szydlo R et al (2021) TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. Br J Haematol 193:346\u2013355. https:\/\/doi.org\/10.1111\/bjh.17286","journal-title":"Br J Haematol"},{"key":"4955_CR61","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","volume":"127","author":"P Jain","year":"2016","unstructured":"Jain P, Kantarjian H, Patel KP et al (2016) Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 127:1269\u20131275. https:\/\/doi.org\/10.1182\/blood-2015-10-674242","journal-title":"Blood"},{"key":"4955_CR62","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.3324\/haematol.2017.168740","volume":"102","author":"S Claudiani","year":"2017","unstructured":"Claudiani S, Apperley JF, Gale RP et al (2017) E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. Haematologica 102:e297\u2013e299. https:\/\/doi.org\/10.3324\/haematol.2017.168740","journal-title":"Haematologica"},{"key":"4955_CR63","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.18632\/oncotarget.27652","volume":"11","author":"A Genthon","year":"2020","unstructured":"Genthon A, Nicolini FE, Huguet F et al (2020) Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib. Oncotarget 11:2560\u20132570. https:\/\/doi.org\/10.18632\/oncotarget.27652","journal-title":"Oncotarget"},{"key":"4955_CR64","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M et al (1984) Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63:789\u2013799","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04955-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04955-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04955-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T06:07:31Z","timestamp":1662703651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04955-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["4955"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04955-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"assertion":[{"value":"3 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all patients for being included in the study. The CML Observatory has been authorised (authorisation no. 914456) by CNIL, the French data protection authority, in accordance with its ethical standards and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. It is promoted by the Clermont-Ferrand University Hospital that is the coordinating centre.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The CML Observatory benefits from industrial support from PFIZER, INCYTE, and NOVARTIS SA; none of these companies had any control over the writing of this manuscript or any influence on data interpretation. Authors HJA, ATu, FH, AG-B, and MGB have received a speaker honorarium from PFIZER, INCYTE, and NOVARTIS SA for educational or scientific projects unrelated to this study. SS, CL, ED, ATc, DH, and BP declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}